Commonwealth Equity Cuts GE HealthCare Technologies Stake by 34.4%; Wedge Capital’s $26.9M Entry
Commonwealth Equity Services LLC sold 91,088 shares of GE HealthCare Technologies Inc. in Q3, reducing its stake by 34.4% to 173,486 shares valued at $13.03 million. Wedge Capital Management established a new position in the company worth approximately $26.86 million, as institutional investors now hold 82.06% of outstanding shares.
1. Major Institutional Stake Reduction
Commonwealth Equity Services LLC reported a 34.4% reduction in its position in GE HealthCare Technologies Inc. during the third quarter, selling 91,088 shares and retaining 173,486 shares valued at approximately $13.03 million according to its latest 13F filing with the SEC. This move follows other reallocations by large funds: Mirae Asset Global Investments increased its holding by 4.2% to 159,882 shares, Wedge Capital Management initiated a new position worth about $26.86 million, and National Bank of Canada FI more than doubled its stake to 899,693 shares, reflecting divergent institutional views on the company’s near-term prospects.
2. Q3 Financial Performance and FY2025 Outlook
In its October quarter, GE HealthCare Technologies reported earnings per share of $1.07, surpassing consensus by $0.02, on revenues of $5.14 billion, a 5.8% year-over-year increase. The company achieved a net margin of 10.94% and a return on equity of 22.52%. Management has set full-year 2025 guidance at an EPS range of $4.51 to $4.63, while analysts, on average, expect $4.68 for the fiscal year, indicating confidence in continued earnings growth driven by strength in diagnostic imaging and lifecycle services.
3. Dividend Policy and Yield
GE HealthCare Technologies announced a quarterly dividend of $0.035 per share, payable February 13 to shareholders of record January 9, corresponding to an annualized payout of $0.14 per share and representing a yield of approximately 0.2%. The company’s payout ratio stands at 2.89%, underscoring its conservative approach to capital return and the potential capacity for reinvestment in R&D and strategic acquisitions.
4. Analyst Ratings and Price Targets
Equity research firms remain broadly positive on GE HealthCare Technologies, with seven analysts maintaining Buy or Outperform ratings and seven issuing Hold recommendations. Stifel Nicolaus recently raised its target from $90 to $95, and Goldman Sachs reaffirmed a Buy rating with a $98 objective. The consensus analyst price target sits at $89.50, reflecting expectations for ongoing market share gains in imaging modalities and growing adoption of digital and software solutions.